Timos Papagatsias/LinkedIn
Jul 11, 2026, 21:44
Timos Papagatsias: From Promising Concepts to Clinical Differentiation at ISTH 2026
Timos Papagatsias, CEO of LucidQuest, shared on X:
“ISTH 2026 will test whether VWD rebalancing, oral FVIII mimicry, next-generation anticoagulants, and AI-enabled diagnostics can move from promising concepts to clinically meaningful differentiation.
Check out LucidQuest’s preview.”
Stay updated with Hemostasis Today.
-
Jul 11, 2026, 21:43Sharing New Research in Hemophilia at ISTH 2026 – Novo Nordisk Medical US
-
Jul 11, 2026, 21:41Bianca Constantin: Don’t Miss the ISTH Early Career Committee Activities
-
Jul 11, 2026, 21:38Fateme Babaha: Don’t Miss Your Favorite ISTH 2026 Sessions
-
Jul 11, 2026, 21:11Farjah Algahtani: Learning, Sharing, and Collaborating at ISTH 2026
-
Jul 11, 2026, 19:56Louise St. Germain Bannon: A Fantastic Start to ISTH 2026 and the Future of Thrombosis Research
-
Jul 11, 2026, 19:38Lynn Kloeckner: Recognizing Kirsten Lacine’s Impact on the Stroke Survivor Journey
-
Jul 11, 2026, 19:19Rens De Groot: New Proteomic Evidence Reveals Early Hemolysis During ADAMTS13 Relapse in Immune TTP
-
Jul 11, 2026, 19:01Laurent Bertoletti: Honoring the Legacy of Guy Meyer and the INNOVTE Network at ISTH 2026
-
Jul 11, 2026, 18:53Pilar de la Rocha Mur: Why Trust Is the Most Valuable Currency in Clinical Research